Monoamine oxidase inhibitory activity in tobacco smoke varies with tobacco type

Tobacco Control

Volumn 21, Issue 1, 2011, Pages 39-43

  Lewis, Amy J ^a,b   Truman, Penelope ^a   Hosking, Matthew R ^a   Miller, John H ^b  

^a INSTITUTE OF ENVIRONMENTAL SCIENCE AND RESEARCH   (New Zealand)

^b VICTORIA UNIVERSITY OF WELLINGTON   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

MONOAMINE OXIDASE INHIBITOR; NICOTINE; TAR;

ARTICLE; CHEMISTRY; HUMAN; METABOLISM; PARTICULATE MATTER; SMOKE; TOBACCO;

HUMANS; MONOAMINE OXIDASE INHIBITORS; NICOTINE; PARTICULATE MATTER; SMOKE; TARS; TOBACCO;

EID: 84857034513     PISSN: 09644563     EISSN: 14683318     Source Type: Journal    
DOI: 10.1136/tc.2010.040287     Document Type: Article

References (25)

1. Gilbert DG, Zuo Y, Browning RA, et al. Platelet monoamine oxidase B activity changes across 31 days of smoking abstinence. Nicotine Tob Res 2003;5:813-19.
2. Fowler JS, Logan J, Wang GJ, et al. Monoamine oxidase and cigarette smoking. Neurotoxicology 2003;24:75-82.
3. Fowler JS, Logan J, Wang GJ, et al. Low monoamine oxidase B in peripheral organs in smokers. Proc Natl Acad Sci U S A 2003;100:11600-5.
4. Lewis A, Miller JH, Lea RA. Monoamine oxidase and tobacco dependence. Neurotoxicology 2007;28:182-95.
5. Castagnoli K, Murugesan T. Tobacco leaf, smoke and smoking, MAO inhibitors, Parkinson's disease and neuroprotection; are there links? Neurotoxicology 2004;25:279-91.
6. Herraiz T, Chaparro C. Human monoamine oxidase is inhibited by tobacco smoke: beta-carboline alkaloids act as potent and reversible inhibitors. Biochem Biophys Res Commun 2005;326:378-86.
7. Yu PH, Boulton AA. Irreversible inhibition of monoamine oxidase by some components of cigarette smoke. Life Sci 1987;41:675-82.
8. Rommelspacher H, Meier-Henco M, Smolka M, et al. The levels of norharman are high enough after smoking to affect monoamineoxidase B in platelets. Eur J Pharmacol 2002;441:115-25.
9. Castagnoli K, Steyn SJ, Magnin G, et al. Studies on the interactions of tobacco leaf and tobacco smoke constituents and monoamine oxidase. Neurotox Res 2002;4:151-60.
10. Rose JE, Behm FM, Ramsey C, et al. Platelet monoamine oxidase, smoking cessation, and tobacco withdrawal symptoms. Nicotine Tob Res 2001;3:383-90.
11. Ambrose V, Miller JH, Dickson SJ, et al. Tobacco particulate matter is more potent than nicotine at up-regulating nicotinic receptors on SH-SY5Y cells. Nicotine Tob Res 2007;9:793-9.
12. Morinan A, Garratt HM. An improved fluorimetric assay for brain monoamine oxidase. J Pharmacol Methods 1985;13:213-23.
13. Laugesen M, Epton M, Frampton CM, et al. Hand-rolled cigarette smoking patterns compared with factory-made cigarette smoking in New Zealand men. BMC Public Health 2009;9:194.
14. Fowles JB. Mainstream Smoke Emissions from 'Roll-Your-Own' Loose-Leaf Tobacco Sold in New Zealand. Wellington, New Zealand. Ministry of Health, 2008. http:// www.moh.govt.nz/moh.nsf/indexmh/mainstream-smoke-emissions (accessed Jun 2010).
15. Benowitz NL, Kuyt F, Jacob P 3rd. Circadian blood nicotine concentrations during cigarette smoking. Clin Pharmacol Ther 1982;32:758-64.
16. Benowitz NL, Hukkanen J, Jacob P 3rd. Nicotine chemistry, metabolism, kinetics and biomarkers. Handb Exp Pharmacol 2009;192:29-60.
17. Guillem K, Vouillac C, Azar MR, et al. Monoamine oxidase inhibition dramatically increases the motivation to self-administer nicotine in rats. J Neurosci 2005;25:8593-600.
18. Villegier AS, Salomon L, Granon S, et al. Monoamine oxidase inhibitors allow locomotor and rewarding responses to nicotine. Neuropsychopharmacology 2006;31:1704-13.
19. Guillem K, Vouillac C, Azar MR, et al. Monoamine oxidase A rather than monoamine oxidase B inhibition increases nicotine reinforcement in rats. Eur J Neurosci 2006;24:3532-40.
20. Breyer-Pfaff U, Wiatr G, Stevens I, et al. Elevated norharman plasma levels in alcoholic patients and controls resulting from tobacco smoking. Life Sci 1996;58:1425-32.
21. Hukkanen J, Jacob P 3rd, Benowitz NL. Metabolism and disposition kinetics of nicotine. Pharmacol Rev 2005;57:79-115.
22. Matta SG, Balfour DJ, Benowitz NL, et al. Guidelines on nicotine dose selection for in vivo research. Psychopharmacology (Berl) 2007;190:269-319.
23. Ministry of Health. Tobacco Facts 2005. Report No. Hp4189. Wellington, New Zealand. Ministry of Health, 2005. http://www.moh.govt.nz/moh.nsf/pagesmh/1854 (accessed Jun 2010).
24. Young D, Borland R, Hammond D, et al. Prevalence and attributes of roll-your-own smokers in the International Tobacco Control (ITC) Four Country Survey. Tob Control 2006;15(Suppl 3):iii76-82.
25. Li J, Grigg M, Weerasekera D, et al. Characteristics and quitting success of roll-yourown versus tailor-made cigarette smokers. N Z Med J 2010;123:64-73.